Audit: QRS - Hyperbaric Oxygen Therapy for Health & Longevity
Audit conducted on 30/08/2026 03:47 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Every populated variable traces to ER text: protocol cells to ER Therapeutic Protocol (lines 392–402), time cells to ER lines 181/187/445, benefit and risk tiers to the ER tier headings, monitoring rows to the ER biomarker table (lines 479–486), cadence to ER lines 473–475, qualitative items to ER lines 490–494. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | ER hedges carried verbatim: “Whether the effect persists beyond hours, or occurs at all in metabolically healthy people, is untested” (time_3_sub) and “No established target; track change from the individual’s own baseline” (marker_6_target). |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindication severity preserved (pneumothorax, bleomycin, pregnancy, NYHA Class IV all remain in the STOP gate); “Not tested head-to-head against the 2.0 ATA course” preserves ER line 396 without weakening. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications come from the ER “Populations who should avoid” list; Key Interactions from the ER interaction bullets; Benefits and Risks from their respective ER tier sections. No Benefit-Modifying or Risk-Modifying Factor is promoted to a gate. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | The QRS carries no PMIDs, author names, NCT identifiers, or brand names anywhere. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind are present in the QRS. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Measured, sceptical register matches the ER, including the ER’s own framing that the boldest ageing claims rest on unvalidated markers. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Targets and thresholds are concrete and numeric while the narrative cells stay plain and non-alarmist. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Content is presented descriptively (“Morning sessions are usual”, “Effects follow cumulative session count”) rather than as instructions. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No imperative or prescriptive constructions; the monitoring cadence describes established practice drawn from ER lines 473–475. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No occurrence of “recommend”, “advise”, “should”, or “must” anywhere in the document body. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns appear in the document. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms are limited to biomarker names and protocol units carried from the ER; the narrative cells use plain wording. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Gate and tier items are bare noun phrases; protocol subs are single clauses. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed: no “you”/”your” anywhere in the file. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Framing throughout assumes an adult evaluating an elective 60-session course, with screening, targets, and cost trade-offs surfaced. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | The at-a-glance states the 150–200 hour and five-figure cost without hedging it as prohibitive. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Content presumes access to cardiopulmonary exercise testing, cycloplegic refraction, spirometry, and tympanometry. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | time_2_sub notes the sedentary over-64 sample “so trained individuals may have less headroom”; time_3_sub notes the effect is untested in metabolically healthy people. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “Standard longevity protocol” is used; the string “anti-aging” does not occur. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Clinical register throughout (“barotrauma”, “hypoglycaemia”, “myopic shift”, “cerebral arterial gas embolism”); the plain wording in at-a-glance is the ER Conclusion’s own phrasing and required by 7.4. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed headings, gate headings, tier labels, and the three monitoring column headers match the template byte-for-byte. |
| 3.2 | All “<span data-qrs-var=”NAME”>…</span>” from the [qrs_template] are present in the the QRS. | 🟢 | All 38 template variable names are present; the repeatable marker_#_* set is expanded to 8 rows and qualitative_item_# to 5 items, giving 63 spans, each occurring exactly once. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | A normalised diff against the template shows differences only inside data-qrs-var regions; CSS, the header subline, the website="..." spans, and the footer disclaimer are unchanged. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section that feeds the QRS is empty; all four benefit tiers, all four risk tiers, the contraindication list, the interaction list, the monitoring table, and the qualitative list are populated in the ER. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels “Standard longevity protocol”, “Alternative shorter protocol”, and “Session continuity matters more than timing” are the ER’s bold labels verbatim (ER lines 392, 394, 402). |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Time-to-effect labels reuse the ER benefit headings verbatim (“Cognitive Performance”, “Cardiorespiratory Fitness and Cardiac Perfusion”, “Insulin Sensitivity and Fasting Glucose”); marker names match the ER biomarker table verbatim. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji characters occur in the file; the ER’s “⚠️ Conflicted” markers on Cognitive Performance and Exercise-Induced Muscle Damage were correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Section budgets respected: 8 contraindications, 9 interactions, three items per benefit/risk tier, 8 monitoring rows, 5 qualitative items; no structural additions to the template. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14: the metadata comment immediately follows <!doctype html> on line 1 and precedes the “blank template” comment on line 16. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- on line 3, closing --- on line 13; the title text on line 2 precedes the opening delimiter. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | It sits inside an HTML comment and no metadata value is echoed into the body. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All values are trimmed and unquoted except duration: "00:03", which contains a colon and therefore requires quoting. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: hyperbaric_oxygen_therapy_2026-0830-0002_Opus_ER.md, matching the ER’s own filename field (ER line 17). |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the version badge at the top of QRS.md. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0830-0331, correct YYYY-MMDD-HHMM form. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” is nickname plus version number with no qualifier appended. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9: qrs_filename: hyperbaric_oxygen_therapy_2026-0830-0002_Opus_QRS.html, matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all eight keys; only the colon-bearing duration value is quoted. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Hyperbaric Oxygen Therapy for Health & Longevity - Quick Reference Sheet”, matching ER canonical_topic (ER line 8) with the ampersand encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “Hyperbaric Oxygen Therapy for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: “08/30/2026”, the correct MM/DD/YYYY rendering of 2026-0830-0331. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”, matching the frontmatter value. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header block matches the template exactly; the ER’s “Also known as” line was not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Three sentences mapping to the three Conclusion paragraphs (ER lines 516, 518, 520): what it is, mixed results plus unvalidated markers, and cost against payoff. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 56 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | “finite course… pressurised chamber breathing pure oxygen” (ER 516), “thinking, fitness, blood sugar handling and pain… genuinely mixed” (ER 516), “markers that have never been tied to any real-world outcome” (ER 518), “150 to 200 hours and a five-figure sum, with predictable ear and vision effects and a small chance of a seizure” (ER 520). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; the ER Conclusion’s plain equivalents are used (“thinking”, “blood sugar handling”, “cell-ageing claims”). |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No study names, years, or sample sizes appear. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | The only figures are resource costs (150–200 hours, five figures), not statistics. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All eight items come from the “Populations who should avoid Hyperbaric Oxygen Therapy” list (ER lines 359–366). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All eight ER avoid-population bullets are present, in ER order, with none added or omitted. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Lines 576–583: eight discrete <li> elements inside the stop_items span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Trailing clauses stripped throughout: “— the one absolute contraindication in every guideline” (ER 359), the pulmonary-oedema rationale (ER 365), and “which lowers the seizure threshold” (ER 366) are all removed. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “(New York Heart Association Class IV, or ejection fraction under 35%)”, “within the preceding 6 months”, “of any size”, “until resolved”, and “outside emergency carbon monoxide poisoning” are all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section; thresholds are written out in words (“ejection fraction under 35%”). |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER names eight avoid-populations, and the section is correspondingly populated rather than empty. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!– empty: ER names no population that should avoid the intervention –> | N/A | The section is not empty, so no empty-state HTML comment is required. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All nine items come from the ER interaction bullets at lines 339–355. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All nine non-bleomycin interaction bullets are present; bleomycin (ER 337, an absolute contraindication also listed in the avoid-population list) is correctly excluded here and carried in [stop_items] instead. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Lines 591–599: nine discrete <li> elements inside the caution_items span. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every mechanism and mitigation clause is stripped, e.g. the superoxide-dismutase rationale for disulfiram (ER 341) and the pre-session glucose mitigation for insulin (ER 345). |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Example drug lists retained verbatim for decongestants, antioxidants, and nitric oxide supplements; “during active treatment” retained for cisplatin/doxorubicin; “(acetazolamide, a diuretic used for glaucoma and altitude sickness)” trimmed to “(acetazolamide)” and “(oral drugs forcing pancreatic insulin release)” shortened to “(oral diabetes drugs)”, the ER’s own alternative wording at line 275. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section; parentheticals are plain comma-separated drug lists. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER names ten interaction bullets, and the section is correspondingly populated rather than empty. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!– empty: ER names no interaction that changes how the intervention is used –> | N/A | The section is not empty, so no empty-state HTML comment is required. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells derive from the ER Therapeutic Protocol section (lines 392, 394, 396, 400, 402). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | The two dosing regimens that define the intervention (standard 60-session 2.0 ATA course and the 40-session 1.5 ATA alternative) plus session continuity, which governs whether a course counts at all. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER Therapeutic Protocol section contains eleven bullets, well above three, and all three action sets are populated. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine action variables carry substantive ER-derived content; none retains a template placeholder. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Cognitive performance, cardiorespiratory fitness/cardiac perfusion, and insulin sensitivity — the three ER outcomes for which an onset interval is actually stated. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered High tier (Cognitive Performance) then the two Medium-tier outcomes in ER order (Cardiorespiratory Fitness before Insulin Sensitivity). The other High-tier benefits (wound healing, fibromyalgia) carry no onset interval in the ER. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies at least three distinct onset intervals, and all three time sets are populated. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine time variables carry ER-derived content, e.g. time_3_sub reproduces ER line 187 verbatim and time_1_sub reproduces ER line 445. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information (ER line 445 plus the per-benefit intervals), so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All eleven listed benefits correspond one-to-one with the ER Expected Benefits subheadings (ER lines 159–223). |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans are present and populated at lines 544–566, each in its correct ER tier. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each tier is a semicolon-separated list of bare benefit names; no magnitudes, sample sizes, or mechanisms are carried across. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses occur in any benefit item; the ER’s “⚠️ Conflicted” qualifiers on Cognitive Performance and Exercise-Induced Muscle Damage are also dropped. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER benefit tiers contain items, so no span needed hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All eleven listed risks correspond one-to-one with the ER Potential Risks & Side Effects subheadings (ER lines 247–313). |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans are present and populated at lines 611–634, each in its correct ER tier. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each tier is a semicolon-separated list of bare risk names; the ER’s incidence figures (43.2%, 0.024% per treatment, 0.5–1.5%) are all omitted. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses occur in any risk item. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER risk tiers contain items, so no span needed hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | The table reproduces the ER Monitoring Protocol & Defining Success biomarker table (ER lines 477–486). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All eight ER rows are present in ER order: capillary blood glucose, HbA1c, hs-CRP, haemoglobin/full blood count, spirometry, cycloplegic refraction, VO2max, tympanometry — with targets and rationales carried verbatim. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Lines 772–777 condense ER lines 473–475: baseline panel before session one, per-session glucose on insulin or a sulfonylurea, ear examination on any pain report, and repeats at course end, 6 and 12 months. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All five items come from the qualitative-marker bullet list in the ER Monitoring Protocol & Defining Success section (ER lines 490–494). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All five ER bullets are present verbatim and in ER order: sleep quality, daytime energy and post-session fatigue, cognitive clarity, exercise tolerance, and ear/facial/vision symptoms. |
Issues 30/08/2026 03:47
Pass rate 100.00%. No issues found.
Issues 30/08/2026 03:41
- 1.3 — Session-gap rule strengthened: [action_3_value] at line 480 reads “Gaps made up, not skipped”, but ER line 402 states “Gaps longer than a few days are generally made up rather than skipped” — the QRS drops both the “longer than a few days” threshold and the “generally” hedge, converting a conditional practice into an absolute rule.
- 9.5 — Insulin parenthetical dropped: [caution_items] line 594 reads “Insulin and sulfonylureas”, dropping the ER’s parenthetical gloss “(oral drugs forcing pancreatic insulin release)” (ER line 345) entirely, while neighbouring items retain or trim their glosses.
Fixes 30/08/2026 03:41
- 1.3 — Session-gap qualifier restored: [action_3_value] changed from “Gaps made up, not skipped” to “Gaps over a few days generally made up”, restoring the ER’s threshold and its “generally” hedge (ER line 402).
- 9.5 — Insulin parenthetical restored: [caution_items] changed from “Insulin and sulfonylureas” to “Insulin and sulfonylureas (oral diabetes drugs)”, reinstating the ER’s parenthetical gloss in trimmed form.
Issues 30/08/2026 03:35
- 12.3 / 12.4 — “(conflicted)” qualifier retained in Benefits: [benefits_high] carries “cognitive performance (conflicted)” (QRS line 546) and [benefits_low] carries “Recovery from exercise-induced muscle damage (conflicted)” (QRS line 558); parenthetical evidence-strength qualifiers must be stripped because the tier already encodes evidence strength.
- 1.1 — Unsupported durability claim in Time to Effect: [time_2_sub] states “Durability beyond course end untested for this outcome” (QRS lines 518-519), a claim the ER never makes — its durability bullet (ER line 423) covers only post-COVID gains and telomere/senescence markers.
Fixes 30/08/2026 03:35
- 12.3 / 12.4 — “(conflicted)” qualifier stripped: Removed the parenthetical “(conflicted)” from “cognitive performance” in [benefits_high] and from “Recovery from exercise-induced muscle damage” in [benefits_low], leaving the bare benefit names.
- 1.1 — Unsupported durability claim replaced: [time_2_sub] changed from “Daily sessions; measured in sedentary adults over 64. Durability beyond course end untested for this outcome” to “Daily sessions; measured in sedentary adults over 64, so trained individuals may have less headroom”, which is supported verbatim by the ER’s cardiorespiratory fitness entry.